Studies involving individuals with T1D have shown promising results, such as reduced insulin needs, minimized glucose variability, weight loss, and better post-meal glucose control.10, , , , , , , -18 In addition, GLP-1 RAs have been shown to improve cardiovascular and renal outcomes in patients with T2D19,20 and T1D.21 Although not FDA approved for T1D, several healthcare providers prescribe GLP-1 RAs off-label, especially for patients facing insulin resistance and obesity. The gene discussed is GCG; the disease is Obesity.